Rheumatology

Roy Fleischmann, MD, examines the current state of biosimilars as it relates to rheumatologists in the United States.

More than 50% of patients with classified SLE at Washington University’s Lupus Clinic exhibit clinically meaningful and persistent depression and anxiety symptoms over time.

Roy Fleischmann, MD, explains the history of biosimilars in rheumatology as well as implementing biosimilars in the United States.

The panel explains the many conventional DMARDs that can be used to treat psoriatic arthritis, as well as their role in management.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, talk about the importance of shared decision-making in the treatment of psoriatic arthritis.

Thought leaders discuss differences in recommendations between guidelines for the management of psoriatic arthritis.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, discuss the common triggers patients with psoriatic arthritis and the importance of stress management.

Titled, "Biosimilars in Rheumatology: Past, Present, and Future," this 3-part video series explores the origins of biosimilars, where we are currently, and hypothesizes about the future of biosimilars in the United States.

In this Q&A, Krzysztof Bonek, MD, PhD, discussed the findings of his study that looked at the associations of IL-18 serum levels with serum lipids, cardiovascular risk and disease activity in patients with ankylosing spondylitis and psoriatic arthritis.

When patients undergo surgery for hip and knee replacements, adjustment to their rheumatoid arthritis care may be required. Test your knowledge of how to manage patients undergoing these types of surgery in this quiz.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 5, 2021.

The American College of Rheumatology (ACR) has published guidance regarding the management of juvenile idiopathic arthritis, with emphasis placed on the treatment of systemic JIA and oligoarthritis, as well as non-pharmacologic therapies.

The American College of Rheumatology releases 2 new guidelines for treating patients with juvenile idiopathic arthritis.

Types of patient populations at higher risk for developing more severe forms of lupus.

Criteria used by rheumatologists to help classify lupus due to its heterogenous manifestation.

Aspartyl-alanyl-diketopiperazine (Ampion), an intra-articular injection, works to regulate immune responses that are connected to pain, inflammation, and joint damage in patients with osteoarthritis of the knee.

In rheumatoid arthritis, a treat-to-target approach aims for remission or low disease activity within the first 3 months. However, investigators noted that improvements continued to increase throughout the 52-week period.

New recommendations were released by ACR and AAHKS regarding perioperative management of antirheumatic medications for patients with rheumatic diseases undergoing these procedures.

Rheumatology Network interviewed Jeffrey Stark, MD, to discuss the BE COMPLETE study, which examined the efficacy of bimekizumab for treating psoriatic arthritis.

"For many years we lacked access to novel therapeutics in SLE and our outcomes frequently reflected this," stated Jack Arnold, MBBS, MRCP. "However, with new targeted therapies, we appear to be entering a new era where treatment decisions will require more nuanced thought."

The long-term success of any psoriatic arthritis treatment may be predictable as early as 3 months if a timely assessment and adjustment of disease management is prioritized.

Expert John Sergent, MD, goes into detail about myositis and how to differentiate it from other inflammatory diseases.

“This dramatic change in healthcare delivery led to significant challenges amongst healthcare management teams, healthcare professionals as well as patients, especially during the early phases of implementation," investigators stated.

These prominent leaders in the field of autoimmune disease discuss AHN's Autoimmunity Institute joining forces with the Relapsing Polychondritis Foundation.

Why is Rare Disease Day so important? Hear the answers from some of the most qualified professionals in rare disease fields.

Results indicated that a brief methotrexate withdrawal after COVID-19 vaccine doses may improve immunogenicity in patients with rheumatoid arthritis.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 25, 2021.

Uma Mahadevan, MD, gives Rheumatology Network an overview of her Rheumatology Winter Clinical Symposium presentation, “Gastroenterology Update for the Rheumatologist.”

Anisha Dua, MD, MPH, discusses the mimics, related conditions, and new diseases in the field of vasculitis as it relates to rheumatology.

On this month's episode of Overdrive, Rheumatology Network interviewed Terence Rooney, MD, to discuss the findings of a network meta-analysis that examined the efficacy of guselkumab (TREMFYA) for skin clearance and joint improvements in patients with psoriatic arthritis.